-
Something wrong with this record ?
Synthetic Aminoindanes: A Summary of Existing Knowledge
N. Pinterova, RR. Horsley, T. Palenicek,
Language English Country Switzerland
Document type Journal Article, Review
NLK
Directory of Open Access Journals
from 2009
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- Publication type
- Journal Article MeSH
- Review MeSH
Objectives: Aminoindanes ("bath salts," a class of novel psychoactive substances, NPSs) increased rapidly in popularity on the recreational drug market, particularly after mephedrone and other synthetic cathinones were banned in the UK in 2010. Novel aminoindanes continue to emerge, but relatively little is known about their effects and risks. Their history, chemistry, pharmacology, behavioral effects, pharmacokinetics, and toxicity are reviewed in this paper. Methods: Scientific literature was searched on ISI Web of Knowledge: Web of Science (WoS) during June and July 2017, using English language terms: aminoindanes such as 5,6-methylenedioxy-2-aminoindane (MDAI), 5-iodo-2-aminoindane (5-IAI), 2-aminoindane (2-AI), 5,6-methylenedioxy-N-methyl-2-aminoindane (MDMAI), and 5-methoxy-6-methyl-2-aminoindane (MMAI). WoS was selected as it searches several databases simultaneously and has quality criteria for inclusion. For typical use and effects, Erowid, PsychonautWiki, Bluelight, and Drugs-Forum were searched; for legal status and epidemiology, the European Information System and Database on New Drugs (EDND) was used. Results: Aminoindanes were first synthesized for medical use, e.g., as anti-Parkinsonian drugs and later as a potential compound facilitating psychotherapy; however, they are now widely substituted for ecstasy. Their mechanisms of action (primarily via serotonin) mean that they may pose a significant risk of serotonin syndrome at high doses or when combined with other drugs. Fatally toxic effects have been observed both in the laboratory in animal studies and in clinic, where deaths related with aminoindanes have been reported. Conclusion: Greater knowledge about aminoindanes is urgently required to decrease risks of fatal intoxication, and appropriate legislation is needed to protect public health without impeding research.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18000907
- 003
- CZ-PrNML
- 005
- 20180122135034.0
- 007
- ta
- 008
- 180116s2017 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fpsyt.2017.00236 $2 doi
- 035 __
- $a (PubMed)29204127
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Pinterova, Nikola $u National Institute of Mental Health, Klecany, Czechia. 3rd Medical Faculty, Charles University, Prague, Czechia.
- 245 10
- $a Synthetic Aminoindanes: A Summary of Existing Knowledge / $c N. Pinterova, RR. Horsley, T. Palenicek,
- 520 9_
- $a Objectives: Aminoindanes ("bath salts," a class of novel psychoactive substances, NPSs) increased rapidly in popularity on the recreational drug market, particularly after mephedrone and other synthetic cathinones were banned in the UK in 2010. Novel aminoindanes continue to emerge, but relatively little is known about their effects and risks. Their history, chemistry, pharmacology, behavioral effects, pharmacokinetics, and toxicity are reviewed in this paper. Methods: Scientific literature was searched on ISI Web of Knowledge: Web of Science (WoS) during June and July 2017, using English language terms: aminoindanes such as 5,6-methylenedioxy-2-aminoindane (MDAI), 5-iodo-2-aminoindane (5-IAI), 2-aminoindane (2-AI), 5,6-methylenedioxy-N-methyl-2-aminoindane (MDMAI), and 5-methoxy-6-methyl-2-aminoindane (MMAI). WoS was selected as it searches several databases simultaneously and has quality criteria for inclusion. For typical use and effects, Erowid, PsychonautWiki, Bluelight, and Drugs-Forum were searched; for legal status and epidemiology, the European Information System and Database on New Drugs (EDND) was used. Results: Aminoindanes were first synthesized for medical use, e.g., as anti-Parkinsonian drugs and later as a potential compound facilitating psychotherapy; however, they are now widely substituted for ecstasy. Their mechanisms of action (primarily via serotonin) mean that they may pose a significant risk of serotonin syndrome at high doses or when combined with other drugs. Fatally toxic effects have been observed both in the laboratory in animal studies and in clinic, where deaths related with aminoindanes have been reported. Conclusion: Greater knowledge about aminoindanes is urgently required to decrease risks of fatal intoxication, and appropriate legislation is needed to protect public health without impeding research.
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Horsley, Rachel R $u National Institute of Mental Health, Klecany, Czechia.
- 700 1_
- $a Palenicek, Tomas $u National Institute of Mental Health, Klecany, Czechia. 3rd Medical Faculty, Charles University, Prague, Czechia.
- 773 0_
- $w MED00174602 $t Frontiers in psychiatry $x 1664-0640 $g Roč. 8, č. - (2017), s. 236
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29204127 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180116 $b ABA008
- 991 __
- $a 20180122135315 $b ABA008
- 999 __
- $a ind $b bmc $g 1268302 $s 997569
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 8 $c - $d 236 $e 20171117 $i 1664-0640 $m Frontiers in psychiatry $n Front Psychiatry $x MED00174602
- LZP __
- $a Pubmed-20180116
